# The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery

> **NCT05560035** · NA · UNKNOWN · sponsor: **General Hospital of Ningxia Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Cervical Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Lidocaine
- **OTHER:** Normal saline (NS)

## Key facts

- **NCT ID:** NCT05560035
- **Lead sponsor:** General Hospital of Ningxia Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05560035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05560035, "The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05560035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*